Unraveling HDAC11: Epigenetic orchestra in different diseases and structural insights for inhibitor design

• Published in: Biochemical pharmacology 2024-07, Vol.225, p.116312, Article 116312
• Main Authors: Khatun, Samima, Prasad Bhagat, Rinki, Dutta, Ritam, Datta, Anwesha, Jaiswal, Abhishek, Halder, Swapnamay, Jha, Tarun, Amin, Sk. Abdul, Gayen, Shovanlal
• Format: Article
• Language: English
• Subjects: Cancer; Chemotherapy; Epigenetics; HDAC11; Structure-activity relationship
• ISSN: 0006-2952; 1873-2968; 1873-2968
• DOI: 10.1016/j.bcp.2024.116312

[Display omitted] Histone deacetylase 11 (HDAC11), a member of the HDAC family, has emerged as a critical regulator in numerous physiological as well as pathological processes. Due to its diverse roles, HDAC11 has been a focal point of research in recent times. Different non-selective inhibitors are already approved, and research is going on to find selective HDAC11 inhibitors. The objective of this review is to comprehensively explore the role of HDAC11 as a pivotal regulator in a multitude of physiological and pathological processes. It aims to delve into the intricate details of HDAC11′s structural and functional aspects, elucidating its molecular interactions and implications in different disease contexts. With a primary focus on elucidating the structure–activity relationships (SARs) of HDAC11 inhibitors, this review also aims to provide a holistic understanding of how its molecular architecture influences its inhibition. Additionally, by integrating both established knowledge and recent research, the review seeks to contribute novel insights into the potential therapeutic applications of HDAC11 inhibitors. Overall, the scope of this review spans from fundamental research elucidating the complexities of HDAC11 biology to the potential of targeting HDAC11 in therapeutic interventions.